YS vs. FBLG, VRCA, STTK, ACIU, ORGO, AMRN, ANRO, PGEN, SKYE, and LLY
Should you be buying YS Biopharma stock or one of its competitors? The main competitors of YS Biopharma include FibroBiologics (FBLG), Verrica Pharmaceuticals (VRCA), Shattuck Labs (STTK), AC Immune (ACIU), Organogenesis (ORGO), Amarin (AMRN), Alto Neuroscience (ANRO), Precigen (PGEN), Skye Bioscience (SKYE), and Eli Lilly and Company (LLY). These companies are all part of the "pharmaceutical preparations" industry.
FibroBiologics (NASDAQ:FBLG) and YS Biopharma (NASDAQ:YS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability, media sentiment and community ranking.
In the previous week, YS Biopharma had 3 more articles in the media than FibroBiologics. MarketBeat recorded 4 mentions for YS Biopharma and 1 mentions for FibroBiologics. FibroBiologics' average media sentiment score of 1.42 beat YS Biopharma's score of 1.19 indicating that YS Biopharma is being referred to more favorably in the news media.
YS Biopharma has a consensus target price of $5.25, suggesting a potential upside of 528.74%. Given FibroBiologics' higher possible upside, analysts clearly believe YS Biopharma is more favorable than FibroBiologics.
52.6% of YS Biopharma shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
YS Biopharma received 1 more outperform votes than FibroBiologics when rated by MarketBeat users.
FibroBiologics has higher earnings, but lower revenue than YS Biopharma.
Summary
YS Biopharma beats FibroBiologics on 7 of the 8 factors compared between the two stocks.
Get YS Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for YS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding YS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
YS Biopharma Competitors List
Related Companies and Tools
